HS

Histogen IncOOTC HSTO Stock Report

Last reporting period 30 Sep, 2023

Updated 31 Oct, 2024

Last price

Market cap $B

0.001

Micro

Exchange

OOTC - OTC

HSTO Stock Analysis

HS

Uncovered

Histogen Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-42/100

Low score

Market cap $B

0.001

Dividend yield

Shares outstanding

4.272 B

Histogen Inc. is a clinical-stage therapeutics company. The Company is focused on developing its hypoxia-generated growth factor technology platform and stem cell-free biologic products as restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function. The Company's product pipelines include CCM Cosmetics, HST 003, HST 004, and Emricasan. In addition, within its small molecule pipeline, its product candidates also include CTS-2090 and CTS-2096. Its HST-003 is a human extracellular matrix (hECM), which is focused on regenerating hyaline cartilage for the treatment of articular cartilage defects in the knee, with a malleable scaffold that stimulates the body’s own stem cells. HST 004 is a cell conditioned medium (CCM) solution, which is used for treatment of spinal disc repair. Emricasan is an orally active pan-caspase inhibitor being developed for the treatment of COVID-19.

View Section: Eyestock Rating